S&P Corrects And Publishes Its 'D' Issue Rating On €169 Mil Total Return Notes Due 2013 Issued By Natixis S.A. In 2007 Mar 11

  • ID: 2044826
  • March 2011
  • Standard & Poors
1 of 3

Due to an administrative error, the public issue rating we assigned in January 2007 to the €169,000,000 Total Return Notes (TRNs) issued in 2007 by French bank Natixis S.A. (then called IXIS) was not entered into our database. As a result, the issue rating on the TRNs was neither published nor updated. We are correcting this error by publishing the current 'D' issue rating on the TRNs and entering it into our database. We are also providing the rating history on the TRNs. PARIS (Standard & Poor's) March 10, 2011--Standard & Poor's Ratings Services today published its current 'D' issue rating and provided the rating transitions on the €169,000,000 Total Return Notes (TRNs) due 2013 issued in January 2007 by...

Companies mentioned in this report are:
- Natixis S.A.

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Natixis S.A.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.